Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
-0.36 (-0.27%)
Real-time:   3:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 129.85 - 132.41
52 week 83.16 - 140.72
Open 131.85
Vol / Avg. 2.46M/5.17M
Mkt cap 103.45B
P/E 49.59
Div/yield     -
EPS 2.64
Shares 790.54M
Beta 0.99
Inst. own 83%
Oct 21, 2015
Q3 2015 Celgene Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 23, 2015
Q2 2015 Celgene Corp Earnings Release
Jul 23, 2015
Q2 2015 Celgene Corp Earnings Call
Jun 17, 2015
Celgene Corp Annual Shareholders Meeting
Jun 10, 2015
Celgene Corp at William Blair Annual Growth Stock Conference
Jun 9, 2015
Celgene Corp at Goldman Sachs Healthcare Conference
Jun 4, 2015
Celgene Corp at Citi "Slice of the US" Conference
May 31, 2015
Celgene Corp at American Society of Clinical Oncology Annual Meeting
May 28, 2015
Celgene Corp at Sanford C Bernstein Strategic Decisions Conference
May 17, 2015
Celgene Corp at Digestive Disease Week Annual Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 15.64% 26.07%
Operating margin 18.11% 32.79%
EBITD margin - 38.35%
Return on average assets 8.11% 13.02%
Return on average equity 21.83% 33.02%
Employees 6,012 -
CDP Score - 85 B


86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Officers and directors

Robert J. Hugin Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. President, Research and Early Development
Age: 61
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 54
Bio & Compensation  - Reuters
Perry A. Karsen Chief Executive Officer of Celgene Cellular Therapeutics
Age: 60
Bio & Compensation  - Reuters
Scott A. Smith President - Inflammation & Immunology
Age: 53
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters
Richard W. Barker OBE Independent Director
Age: 66
Bio & Compensation  - Reuters